Demosthenes Bouros1, Zoe Daniil2, Despoina Papakosta3, Katerina M Antoniou4, Katerina Markopoulou5, Likurgos Kolilekas6, George Konstantopoulos7, Spyros Papiris8. 1. 1st Academic Department of Pneumonology, Hospital for Diseases of the Chest "Sotiria," Medical School, National and Kapodistrian University of Athens, Athens, Greece. 2. Respiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa, Greece. 3. Pulmonary Medicine Department, General Hospital of Thessaloniki "G. Papanikolaou," Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece. 4. Thoracic Medicine Department, University Hospital of Heraklion, Heraklion, Greece. 5. NHS Pulmonology Department, General Hospital of Thessaloniki "G. Papanikolaou,", Thessaloniki, Greece. 6. NHS 7th Pulmonary Department and Asthma Center, Hospital for Diseases of the Chest "Sotiria,", Athens, Greece. 7. BI Hellas, Medical Department, Athens, Greece. 8. 2nd Respiratory Medicine Department, Medical School, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown origin. Despite the fact that the guidelines on the diagnosis and management of the disease were updated in 2015, incorporating novel agents recently introduced in the therapeutic approach of IPF, there is a lack of data on the epidemiology, disease status, and treatment in clinical practice. Contemporary data provided by national registries in IPF provide valuable information to guide clinical management of the disease in the real-world setting, adjusted to the local needs. OBJECTIVE: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) is a Greek observational registry aiming at gaining further knowledge on the characteristics, management, progression, and outcomes of patients with IPF treated under real-world, clinical practice conditions in Greece. METHODS: Approximately 300 patients will be enrolled consecutively in seven reference centers, constituting the largest IPF registry ever established in Greece. CONCLUSION: This registry is expected to provide data on the characteristics of IPF patients in Greece and the entire clinical management during the course of the disease.
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown origin. Despite the fact that the guidelines on the diagnosis and management of the disease were updated in 2015, incorporating novel agents recently introduced in the therapeutic approach of IPF, there is a lack of data on the epidemiology, disease status, and treatment in clinical practice. Contemporary data provided by national registries in IPF provide valuable information to guide clinical management of the disease in the real-world setting, adjusted to the local needs. OBJECTIVE: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) is a Greek observational registry aiming at gaining further knowledge on the characteristics, management, progression, and outcomes of patients with IPF treated under real-world, clinical practice conditions in Greece. METHODS: Approximately 300 patients will be enrolled consecutively in seven reference centers, constituting the largest IPF registry ever established in Greece. CONCLUSION: This registry is expected to provide data on the characteristics of IPF patients in Greece and the entire clinical management during the course of the disease.
Authors: Daniel A Culver; Jürgen Behr; John A Belperio; Tamera J Corte; Joao A de Andrade; Kevin R Flaherty; Mridu Gulati; Tristan J Huie; Lisa H Lancaster; Jesse Roman; Christopher J Ryerson; Hyun J Kim Journal: Am J Respir Crit Care Med Date: 2019-07-15 Impact factor: 21.405
Authors: Katy C Norman; David N O'Dwyer; Margaret L Salisbury; Katarina M DiLillo; Vibha N Lama; Meng Xia; Stephen J Gurczynski; Eric S White; Kevin R Flaherty; Fernando J Martinez; Susan Murray; Bethany B Moore; Kelly B Arnold Journal: Sci Rep Date: 2020-07-21 Impact factor: 4.379